ArticleNature2025
The oestrous cycle stage affects mammary tumour sensitivity to chemotherapy.
Abstract read
In one paragraph
Article in Nature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Mouse genetic mosaic model for basal-like breast cancer reveals disruption of basal-myoepithelial architecture at premalignancy.Research square · 2026Article
- Chemotherapy-induced estradiol reduction is associated with less relief of pre-chemotherapy anxiety in breast cancer patients.Psychoneuroendocrinology · 2026Article
- Epithelial-to-mesenchymal transition as a central driver of tumor cell plasticity.Nature cancer · 2026Review
- Caffeine attenuates cisplatin induced microglial reactivity and cognitive dysfunction.Frontiers in molecular neuroscience · 2026Article
- Clinical practice guidelines for prognosis and follow-up of early-stage breast cancer patients: Chinese Society of Breast Surgery (CSBrS) practice guidelines (2026 edition) Chinese Society of Breast Surgery, Chinese Society of Surgery, Chinese Medical Association.Translational breast cancer research : a journal focusing on translational research in breast cancer · 2026Review
- Association of immuno-inflammatory biomarkers with response to neoadjuvant chemotherapy and prognosis in HER2-positive breast cancer: dual-center clinical evidence.Frontiers in immunology · 2026Article
- Little women: the relevance and reliance on mouse models for mammary gland research and next steps for translation.Journal of mammary gland biology and neoplasia · 2025Review
- Protein Marker-Dependent Drug Discovery Targeting Breast Cancer Stem Cells.International journal of molecular sciences · 2025Review
- Resistance to neoadjuvant chemotherapy in breast cancers: a metabolic perspective.Journal of experimental & clinical cancer research : CR · 2025Review
- Beyond the gender data gap: co-creating equitable digital patient twins.Frontiers in digital health · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Laura BornesDivision of Molecular Pathology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands.ORCID 0000-0001-9721-1223
Lennart J van WindenLaboratory of Clinical Chemistry and Hematology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Veerle C M GeurtsDivision of Tumor Biology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Beaunelle de BruijnVIB Center for Cancer Biology, KU Leuven Department of Oncology, Leuven, Belgium.
Leyla AzarangBiostatistics Centre & Department of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.ORCID 0000-0001-5163-081X
Mirthe LanfermeijerLaboratory of Clinical Chemistry and Hematology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Marika CarusoVIB Center for Cancer Biology, KU Leuven Department of Oncology, Leuven, Belgium.
Natalie ProostMouse Clinic for Cancer and Aging (MCCA) Preclinical Intervention Unit, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Manon BoeijeMouse Clinic for Cancer and Aging (MCCA) Preclinical Intervention Unit, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Jeroen O LohuisDivision of Molecular Pathology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Guillaume BelthierDivision of Molecular Pathology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands.ORCID 0000-0002-4857-0008
Eulàlia Noguera DelgadoDivision of Molecular Pathology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Nadia de GruilDepartment of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands.ORCID 0000-0002-0609-7814
Judith R KroepDepartment of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands.ORCID 0000-0003-2671-1903
Marieke van de VenMouse Clinic for Cancer and Aging (MCCA) Preclinical Intervention Unit, The Netherlands Cancer Institute, Amsterdam, the Netherlands.ORCID 0000-0001-6779-9353
Renee MenezesBiostatistics Centre & Department of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Jelle WesselingDivision of Molecular Pathology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands.ORCID 0000-0002-8940-2676
Marleen KokDivision of Tumor Biology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.ORCID 0000-0001-9043-9815
Sabine LinnDivision of Molecular Pathology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands.ORCID 0000-0001-5541-0347
Annegien BroeksCore Facility Molecular Pathology & Biobanking, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Huub H van RossumLaboratory of Clinical Chemistry and Hematology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.ORCID 0000-0001-5757-9779
Colinda L G J Scheele *VIB Center for Cancer Biology, KU Leuven Department of Oncology, Leuven, Belgium. colinda.scheele@kuleuven.be.ORCID 0000-0001-8999-5451
Jacco van Rheenen *Division of Molecular Pathology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands. j.v.rheenen@nki.nl.ORCID 0000-0001-8175-1647
Funding
Boehringer Ingelheim FoundationEMBO postdoctoral fellowship
Abstract
The response of breast cancer to neoadjuvant chemotherapy (NAC) varies substantially, even when tumours belong to the same molecular or histological subtype
Indexed as
Breast NeoplasmsDrug Resistance, NeoplasmEstrous CycleMacrophagesNeoadjuvant TherapyAnimalsAntineoplastic AgentsCell Line, TumorDisease Models, AnimalEpithelial-Mesenchymal TransitionFemaleHumansMammary Neoplasms, ExperimentalMiceNeoplasm TransplantationPremenopauseAntineoplastic Agents
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.